The UCGI 28 PANIRINOX trial - a randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis

Congress : ESMO

Authors : Thibault Mazard , François Ghiringhelli , Caroline Mollevi , Eric Assenat , Céline Gavoille , Denis Smith , Veronica Pezzella, Romain Meddeb , Brice Pastor, Marc Ychou , Alain R. Thierry PhD.

Experts group or program : Groupe gastro-intestinal (UCGI)

A majority of patients with mCRC are not suitable for potentially curative resection and their management consists in palliative-intended chemotherapy (CT). Nevertheless, it is described that in patients who achieve complete response (CR) with CT alone or after multimodality treatment, median overall survival is significantly longer than in other patients. In combination with CT, anti-EGFR antibodies appear to be the biological agents of choice in order to reach the best response rate as long as tumors are RAS wild-type.To determine RAS and BRAF mutational status, we have already demonstrated the clinical validity and utility of circulating DNA (ctDNA) analysis using IntPlex® method. Selecting patients with this technology, we aim to investigate response rate and outcomes reached with panitumumab in combination with a standard (mFOLFOX6) or an intensified CT regimen (FOLFIRINOX) in RAS and BRAF wild-type (WT) metastatic patients.

En savoir plus